Novartis buys remaining rights to GSK treatment for up to $1 billion ZURICH (Reuters) – Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments.
